ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.21, no.9, pp.1099-1109, 2021 (SCI-Expanded)
Background: After the approval of imatinib, more than 25 antitumor agents targeting kinases have been approved, and several promising candidates are at various stages of clinical evaluation.